Literature DB >> 28093004

Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.

Anna Kieslich1, Peter Ruf2, Horst Lindhofer2, Raynold Buhmann3, Angelika Eggert1, Patrick Hundsdoerfer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28093004     DOI： 10.1080/10428194.2016.1272687

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

Authors:  Roberta Demichelis-Gómez; Daniela Pérez-Sámano; Christianne Bourlon
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

Review 2.  Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.

Authors:  Margaux Lejeune; Murat Cem Köse; Elodie Duray; Hermann Einsele; Yves Beguin; Jo Caers
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

3.  GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.

Authors:  Felix Zirngibl; Sara M Ivasko; Laura Grunewald; Anika Klaus; Silke Schwiebert; Peter Ruf; Horst Lindhofer; Kathy Astrahantseff; Lena Andersch; Johannes H Schulte; Holger N Lode; Angelika Eggert; Kathleen Anders; Patrick Hundsdoerfer; Annette Künkele
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

Review 4.  Redirecting T cells to hematological malignancies with bispecific antibodies.

Authors:  Mireya Paulina Velasquez; Challice L Bonifant; Stephen Gottschalk
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.